219 related articles for article (PubMed ID: 37115489)
21. TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in non-small cell lung cancer via down-regulation of CSF-1R and enhances the anti-tumor effects of anti-PD-1.
Shih CT; Shiau CW; Chen YL; Chen LJ; Chao TI; Wang CY; Huang CY; Hung MH; Chen KF
Cancer Lett; 2021 Feb; 498():142-151. PubMed ID: 33232786
[TBL] [Abstract][Full Text] [Related]
22. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
[TBL] [Abstract][Full Text] [Related]
23. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.
Wen Z; Sun H; Zhang Z; Zheng Y; Zheng S; Bin J; Liao Y; Shi M; Zhou R; Liao W
Cancer Commun (Lond); 2023 May; 43(5):562-581. PubMed ID: 37031362
[TBL] [Abstract][Full Text] [Related]
24. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
Luo F; Luo M; Rong QX; Zhang H; Chen Z; Wang F; Zhao HY; Fu LW
J Immunother Cancer; 2019 Sep; 7(1):245. PubMed ID: 31511071
[TBL] [Abstract][Full Text] [Related]
25. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
[TBL] [Abstract][Full Text] [Related]
26. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
[TBL] [Abstract][Full Text] [Related]
27. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
Lu CS; Lin CW; Chang YH; Chen HY; Chung WC; Lai WY; Ho CC; Wang TH; Chen CY; Yeh CL; Wu S; Wang SP; Yang PC
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243934
[TBL] [Abstract][Full Text] [Related]
28. TNF-Ī±-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy.
De Ridder K; Locy H; Piccioni E; Zuazo MI; Awad RM; Verhulst S; Van Bulck M; De Vlaeminck Y; Lecocq Q; Reijmen E; De Mey W; De Beck L; Ertveldt T; Pintelon I; Timmermans JP; Escors D; Keyaerts M; Breckpot K; Goyvaerts C
Front Immunol; 2022; 13():811867. PubMed ID: 35493461
[TBL] [Abstract][Full Text] [Related]
29. Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer.
Lu CS; Shiau AL; Su BH; Hsu TS; Wang CT; Su YC; Tsai MS; Feng YH; Tseng YL; Yen YT; Wu CL; Shieh GS
J Hematol Oncol; 2020 Jun; 13(1):62. PubMed ID: 32487125
[TBL] [Abstract][Full Text] [Related]
30. Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer.
Luo M; Wang F; Zhang H; To KKW; Wu S; Chen Z; Liang S; Fu L
Signal Transduct Target Ther; 2020 Aug; 5(1):141. PubMed ID: 32855386
[TBL] [Abstract][Full Text] [Related]
31. Cryoablation triggers type I interferon-dependent antitumor immunity and potentiates immunotherapy efficacy in lung cancer.
Gu C; Wang X; Wang K; Xie F; Chen L; Ji H; Sun J
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272564
[TBL] [Abstract][Full Text] [Related]
32. M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer.
Cao L; Che X; Qiu X; Li Z; Yang B; Wang S; Hou K; Fan Y; Qu X; Liu Y
Cancer Manag Res; 2019; 11():6125-6138. PubMed ID: 31308749
[No Abstract] [Full Text] [Related]
33. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the ResponseĀ of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
34. The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity.
Jang JH; Janker F; De Meester I; Arni S; Borgeaud N; Yamada Y; Gil Bazo I; Weder W; Jungraithmayr W
Carcinogenesis; 2019 Apr; 40(2):324-334. PubMed ID: 30698677
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive Integrative Analysis Reveals the Association of
Arora S; Singh P; Ahmad S; Ahmad T; Dohare R; Almatroodi SA; Alrumaihi F; Rahmani AH; Syed MA
Cells; 2021 Aug; 10(8):. PubMed ID: 34440860
[TBL] [Abstract][Full Text] [Related]
36. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
37. The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.
Yang J; Kim SH; Jung EH; Kim SA; Suh KJ; Lee JY; Kim JW; Kim JW; Lee JO; Kim YJ; Lee KW; Kim JH; Bang SM; Lee JS
Thorac Cancer; 2023 Jan; 14(1):52-60. PubMed ID: 36351567
[TBL] [Abstract][Full Text] [Related]
38. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
39. Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade.
Kawada-Horitani E; Kita S; Okita T; Nakamura Y; Nishida H; Honma Y; Fukuda S; Tsugawa-Shimizu Y; Kozawa J; Sakaue T; Kawachi Y; Fujishima Y; Nishizawa H; Azuma M; Maeda N; Shimomura I
Diabetologia; 2022 Jul; 65(7):1185-1197. PubMed ID: 35511238
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer.
Shen X; Zhao Y; Liu G; Zhou HL; Fan J; Zhang L; Li YL; Wang Y; Liang J; Xu ZX
Life Sci; 2020 Sep; 256():117923. PubMed ID: 32522567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
